VV261

VV261 is an orally bioavailable small molecule inhibitor of the urate transporter 1 (URAT1), developed by Vigonvita Life Sciences for the treatment of hyperuricemia and gout. URAT1, encoded by the SLC22A12 gene, is a key transporter located in the renal proximal tubules responsible for the reabsorption of uric acid from the glomerular filtrate back into the bloodstream. By inhibiting URAT1, VV261 promotes the renal excretion of uric acid (uricosuric effect), thereby reducing serum uric acid levels. The drug has been evaluated in Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers, demonstrating a dose-dependent reduction in serum urate.